Date of Award


Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant


Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C


Objective: The objective of this selective EBM review is to determine whether or not “Does Fecal Microbiota Transplantation cause Clinical Remission in Patients with Ulcerative Colitis?”

Study Design: Review of three English language primary studies published in 2015.

Data Sources: Two randomized control trials and a cohort study determining if fecal microbiota transplantation does lead to clinical remission of Ulcerative Colitis were found by using PubMed and Cochrane databases.

Outcome(s) Measured: The outcomes measured in all three studies were patient oriented evidence that matters which is clinical remission. The outcomes in the Moayyedi et al. was measured by the Mayo Score The Rossen et al. study determined clinical remission as SCCAI score ≤ 2 in combination with ≥1 point improvement on the combined Mayo endoscopic score of the sigmoid and rectum, compared to the baseline sigmoidoscopy, 12 weeks after the first treatment. The Wei et al. trail determined clinical remission was defined as IBDQ >170 and Mayo score <2 in Ulcerative Colitis.

Results: This review compares two randomized, double blind, placebo controlled clinical trials and one cohort study in which the Moayyedi et al. and Wei et al. trial proved that Fecal microbiota transplantation is effective in providing clinical remission in patients with active Ulcerative Colitis; however, the Rossen et al. trial showed there was no significant statistical difference between the experimental [FMT-D] and the placebo [FMT-A] group in inducing clinical remission in patients with active Ulcerative Colitis.

Conclusions: Fecal Microbiota Transplantation does seem to provide effective treatment in causing clinical remission of Ulcerative Colitis overall according to the three studies in this review.